Alkermes advances pipeline with progress on ALKS 37
The research pipeline of USA-based Alkermes (NasdaqGS: ALKS) received a shot in the arm with its candidate ALKS 37 faring well in a mid-stage study (n=87) in patients suffering from opioid induced constipation. This is good news for the firm, which recently suffered a setback in its quest of US approval of Bydureon (exenatide extended-release for injectable suspension) under development with Eli Lilly (The Pharma Letter November 15, 2010).
Results revealed that treatment with ALKS 37 reduced constipation arising out of the intake of opioid pain therapies without compromising on the efficacy of the drugs. Alkermes intends to present complete results from the study at an upcoming medical conference.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze